Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing. Go→
News, articles and issues specific to clinical trial practice and implementation at the investigative site level. Go→
News, developments and strategies related to eClinical, data management, data collection, ePRO, and more information technology used in the drug development chain. Go→
News, articles and issues specific to laboratories role in the clinical trial, including ECG, imaging, genotyping, tissue samples and more. Go→
News, developments and strategies for clinical trials conduct in relation to the FDA, EMEA and other global regulatory authorities overseeing the drug development industry. Go→
News, articles and strategies related to clinical trial design which impact postmarketing studies, therapeutic areas, adaptive trials, statistics, protocols and more. Go→
|
|
GeneTex to Release New Antibodies for the Study of DNA Repair in Zebrafish
Publish date: Mar 14, 2013
![]()
PR Newswire IRVINE, Calif., March 14, 2013
IRVINE, Calif., March 14, 2013 /PRNewswire/ -- GeneTex,
a leading manufacturer of high-quality antibodies, is pleased to announce
that it will be launching new antibodies against phosphorylated Histone H2A.X and p53 designed for use with zebrafish samples.
(Photo: http://photos.prnewswire.com/prnh/20111129/LA13485LOGO-b)
The zebrafish is being increasingly utilized as a model organism to study DNA repair. The zebrafish genome contains nearly
all of the genes involved in the different DNA repair pathways, including the genes for the components of the p53-mediated
damage recognition pathway. Furthermore, the embryos can easily be treated with UV or ionizing irradiation to induce
DNA damage. Importantly, the study of individual DNA damage recognition and repair factors is possible with shRNA- or
morpholino-based approaches that are established techniques in the zebrafish field. GeneTex is excited to contribute to zebrafish DNA damage recognition and repair research by offering these two new antibodies.
Phosphorylated histone H2A.X is extremely useful as an early marker of double-strand breaks that can be used to assess the
extent of DSB repair. The p53 antibody will be immensely valuable for those researchers studying DNA damage and apoptotic
mechanisms, with the logical extension into tumorigenesis. These two reagents represent just the beginning of GeneTex's efforts
to establish a diverse catalog of antibody products that perform in the zebrafish system. Therefore, GeneTex is pleased to
announce the launch of these new antibodies against phosphorylated H2A.X and p53 that have been developed specifically for
use with zebrafish. GeneTex's Histone H2A.X (phospho Ser139) antibody has been validated for immunohistochemistry using both whole-mount
and paraffin-embedded zebrafish embryos. The p53
antibody has been validated for western blotting and immunohistochemistry using zebrafish tissues. UV irradiation results
in a marked increase in the intensity of the signal detected by both products, which demonstrates the specificity of these
antibodies. For additional information on GeneTex, Inc. and its zebrafish antibodies, please call toll-free 877-GENETEX (436-3839)
or visit www.genetex.com/zebrafish.
About GeneTex, Inc.
GeneTex, Inc. is an antibody company founded in 1997 by a group of internationally renowned academic scientists. They strive
to produce the highest-quality antibodies and reagents. Their primary
and secondary antibodies are created through a process involving extensive research, development and validation. GeneTex's
catalog has grown to over 55,000 primary antibodies and all are backed by a 100% Satisfaction Guarantee.
Corporate Mission
We strive to serve and accelerate life science research by creating essential life science tools where quality can be found
in every vial. SOURCE GeneTex
|
|